FindTrial
Sign In

Comparison of Dermaroller versus Dermaroller with topical PRP versus glycolic acid chemical peels in melasma

Comparative study of efficacy and safety of microneedling versus combination of microneedling and topical autologous platelet rich plasma versus 30% glycolic acid peels in melasma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/03/031705
Enrollment
60
Registered
2021-03-04
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L818- Other specified disorders of pigmentation

Interventions

Intervention1: Microneedling and topical application of autologous platelet rich plasma: Combination of microneedling with topical autologous platelet rich plasma group- In this group of patients micr

Sponsors

Dr Surabhi Dayal
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients of melasma of epidermal variety (differentiated by Woodâ??s lamp examination) with MASI more than 10 who have not taken treatment for melasma for last 4 weeks will be included in the study.

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating women. 2. Patient with hypersensitivity to formulation used in the study. 3. Patient on any topical and systemic concurrent therapy that can cause facial melanosis in last 4 weeks. 4. Patient with active or recurrent herpes simplex infection, facial warts and molluscum contagiosum. 5. Patient with history of or evidence of hypertrophic scar or keloid formation. 6. Women on oral contraceptives and hormonal replacement therapy. 7. Patient with history of photosensitivity. 8. Patient having active dermatoses of atopic, seborrheic or other eczematous types. 9. Patient on medications such as oral or topical retinoids, 5 Fluorouracil, Imiquimod. 10. History of corticosteroid therapy in last 4 weeks. 11. History of bleeding disorders or on anticoagulant medications (warfarin,heparin,aspirin) 12. Severe systemic illness or malignancy 13. Patient with history of diabetes, collagen vascular disease, skin cancer or solar keratosis. 14. Patient having unrealistic expectations 15. Uncooperative patients

Design outcomes

Primary

MeasureTime frame
Decrease in MELASMA AREA and SEVERITY INDEX scoring(MASI) from baseline to the end of therapyTimepoint: 12 weeks—

Secondary

MeasureTime frame
Decrease in MELASMA QUALITY OF LIFE scoring (MELASQOL scoring) from baseline to the end of therapyTimepoint: 12 weeks—

Countries

India

Contacts

Public ContactDr Meenakshi

Pt. B.D.Sharma PGIMS, Rohtak

surabhidayal7@gmail.com9896205319

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026